Thermo Fisher Scientific Belimumab Recombinant Human Monoclonal Antibody

Applications

• ELISA (ELISA): Assay-dependent

Product Specifications

Product Specific Information

• Endotoxin level: < 0.01 EU/µg (LAL method)
• Use a manual defrost freezer and avoid repeated freeze–thaw cycles.
• Store at 2–8°C for up to one week.
• Store at -20 to -80°C for up to twelve months from the date of receipt.

Target Information

Belimumab is an intravenous immunosuppressant used as an adjunctive treatment for systemic lupus erythematosus (SLE). It is a fully human recombinant IgG1 lambda monoclonal antibody produced from a recombinant NS0 cell line stably transfected with belimumab heavy and light chain genes.
It was the first biological treatment approved for SLE (FDA approval: March 9, 2011).
Belimumab consists of two heavy chains (452 amino acids each) and two light chains (214 amino acids each, lambda subclass).
Post-translational modifications include:

1. N-linked glycosylation on the CH2 domain at Asn303 of the heavy chain
2. Conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate
3. Loss of the C-terminal lysine residue of the heavy chain

Concomitant use with live or inactivated vaccines must be avoided.

For Research Use Only.
Not for use in diagnostic procedures.
Not for resale without express authorization.